Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer

209 Background: Enzalutamide (ENZ) was approved to prolong survival for castration-resistant prostate cancer (CRPC) patients before and after chemotherapy. No factor was identified to predict the effectiveness of ENZ so far. .Intraductal carcinoma of the prostate (IDC-P) was newly recognized on 2017 EAU guideline and considering as a poor prognostic factor、although there has been no reports to predict the therapeutic effects of ENZ according to the presence of IDC-P. In this study, we evaluated the efficacy of ENZ for CRPC patients with or without IDC-P. Methods: We retrospectively identified 199 CRPC patients treated with ENZ from 2014 to 2018 in author-affiliated hospitals. All needle biopsy slides were reviewed by a single genitourinary pathologist and IDC-P was defined according to the criteria of McNeal at initial biopsy. Endpoint is overall survival (OS) from the time of CRPC diagnosis and time to treatment failure of ENZ. PSA response is defined as over 50% PSA decline from baseline. Results: The median patient age was 71 (range, 49–90) years. The median initial PSA was 154 ng/ml (range, 3.9–24736 ng/ml). The patients who received docetaxel were 42/199 (21%). IDC-P was detected in 98 patients (49%) at initial prostate biopsy. PSA response was 70.5% in patients without IDC-P and 53.9% in patients with IDC-P. The median OS from the time of CRPC was 37.9 and 71.5 months with and without IDC-P, respectively (P=0.013). There was no significant difference on OS in CRPC patients with IDC-P between before and after docetaxel (P=0.941). Same result was observed in CRPC patients without IDC-P (P=0.86). In time to treatment failure by ENZ, patients with IDC-P showed worse prognosis than patients without IDC-P after docetaxel (P=0.068). On the other hand, the difference disappeared before docetaxel regardless the presence of IDC-P (P=0.94). Conclusions: IDC-P is a poor prognostic factor for CRPC patients treated with ENZ. ENZ may be most effective for CRPC patients with IDC-P before chemotherapy.

Download Full-text

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy

Prostate International ◽

10.1016/j.prnil.2018.04.002 ◽

2019 ◽

Vol 7 (1) ◽

pp. 9-14 ◽

Cited By ~ 9

Author(s):

Ayako Ohtaka ◽

Hiroaki Aoki ◽

Masayoshi Nagata ◽

Mayuko Kanayama ◽

Fumitaka Shimizu ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Castration Resistant Prostate Cancer ◽

Poor Prognostic Factor ◽

Castration Resistant

Download Full-text

MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2016.11 ◽

2016 ◽

Vol 19 (3) ◽

pp. 242-247 ◽

Cited By ~ 11

Author(s):

V Genitsch ◽

I Zlobec ◽

G N Thalmann ◽

A Fleischmann

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Advanced Prostate Cancer ◽

Independent Prognostic Factor

Download Full-text

CHRONIC PULMONARY DISEASE IS AN INDEPENDENT PROGNOSTIC FACTOR FOR ADVANCED PROSTATE CANCER

European Urology Supplements ◽

10.1016/s1569-9056(06)60151-6 ◽

2006 ◽

Vol 5 (2) ◽

pp. 58

Author(s):

C.W. Jeong ◽

S.K. Hong ◽

H. Jeong ◽

C. Kwak ◽

E. Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Pulmonary Disease ◽

Advanced Prostate Cancer ◽

Independent Prognostic Factor ◽

Chronic Pulmonary Disease

Download Full-text

The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer

The International Journal of Biological Markers ◽

10.1177/1724600821997461 ◽

2021 ◽

pp. 172460082199746

Author(s):

Juliana Alves de Camargo ◽

Renan Eboli Lopes ◽

Gabriel Fernandes Dias Ferreira ◽

Nayara Izabel Viana ◽

Vanessa Guimaraes ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factors ◽

Prognostic Factor ◽

Single Nucleotide Polymorphisms ◽

Gleason Score ◽

Nucleotide Polymorphisms ◽

Single Nucleotide ◽

Poor Prognostic Factor ◽

Polymorphic Allele

Introduction: Prostate cancer has a high incidence in men and is the second cause of cancer death among americans male. microRNA (miR) is becoming a potential new prognostic factor for prostate cancer. Single nucleotide polymorphisms (SNPs) are common polymorphisms, characterized by a single exchange of nitrogen based in the DNA. This polymorphism is present in the miRs, altering their function. Objective: To evaluate the role of SNP rs1834306 of miR100 and rs2910164 of miR146a in the development and prognosis of prostate cancer. Methods: One hundred patients diagnosed with prostate cancer and 68 controls were selected. The identification of SNP was rated by quantitative polymerase chain reaction from blood samples, and the analysis was performed within the presence of SNP and the prognostic variables. Results: In the SNP rs1834306 (miR100), a smaller presence of the polymorphic homozygous genotype was identified in patients with PSA >10 ng/mL, ( P=0.03); when evaluating only the presence of the polymorphic allele G ( P=0.09) it was compared to the presence of the wild type allele A. Among the patients with prostate cancer, SNP rs2910164 (miR146A), the polymorphic allele was more frequent in patients with a Gleason score ⩾7 than in patients with a Gleason score <7, ( P=0.043). In patients with prostate cancer, miR100 was overexpressed in those with pT3 staging compared to pT2 and among those who had biochemical recurrence ( P = 0.004 and P = 0.011, respectively). Conclusions: SNP of miR146a acts as a poor prognostic factor (Gleason ⩾7), and the SNP of miR100 is linked to better prognostic data (PSA <10). MiR100 was overexpressed in prostate cancer with worse prognostic factors.

Download Full-text